Best for Joint Health

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, demonstrate clinically meaningful efficacy for knee osteoarthritis in humans through both weight loss-dependent and weight loss-independent mechanisms. Multiple RCTs and meta-analyses confirm pain reduction and functional improvement in persons with obesity and osteoarthritis.

Curcumin demonstrates consistent, clinically meaningful improvements in joint pain, stiffness, and function in osteoarthritis and rheumatoid arthritis across multiple human RCTs. Evidence is strong but primarily limited to these two arthritic conditions.

Collagen peptides demonstrate strong, consistent efficacy for reducing joint pain and improving physical function in knee osteoarthritis across multiple well-designed human RCTs. Evidence is robust for symptomatic relief but mechanistic studies suggest minimal effects on cartilage degradation markers or structural joint changes.

Boswellia serrata demonstrates strong evidence for reducing osteoarthritis pain and improving joint function in humans, supported by multiple RCTs and meta-analyses showing clinically meaningful improvements in pain scores, stiffness, and physical function. However, evidence for structural cartilage repair and long-term efficacy remains limited.

Pycnogenol demonstrates consistent efficacy for reducing osteoarthritis pain and improving joint function in multiple human RCTs, with effect sizes ranging from 56% improvement in WOMAC scores to significant reductions in pain intensity. Results are supported by mechanistic evidence showing reduced inflammatory markers and cartilage degradation in severe OA patients.

Creatine monohydrate shows probable benefits for joint health when combined with resistance training in knee osteoarthritis, with evidence of improved physical function and muscle strength. However, efficacy is inconsistent across studies, and some trials found no effect on inflammatory biomarkers or functional recovery.

Ashwagandha demonstrates probable efficacy for joint health, primarily knee osteoarthritis, based on multiple human RCTs showing consistent pain and stiffness reductions. However, evidence remains limited by small sample sizes, short study durations, and inconsistent mechanistic findings across patient populations.

VIP shows probable efficacy for joint health through multiple human observational studies demonstrating anti-inflammatory and cartilage-protective effects in osteoarthritis and rheumatoid arthritis. However, no human RCTs exist, and evidence relies on ex vivo cell studies and observational designs with modest sample sizes.

NAC shows probable efficacy for joint health in humans, with two RCTs and several observational studies demonstrating anti-inflammatory and antioxidant effects in rheumatoid arthritis and osteoarthritis. However, evidence remains limited by small sample sizes and lacks large, independently replicated trials.

Vitamin D3 shows modest benefit for knee osteoarthritis pain and function in some trials, but evidence is mixed with several large RCTs showing no structural benefit or pain reduction. Efficacy is probable but not conclusively proven.

Quercetin shows probable efficacy for joint health based on 4 human RCTs demonstrating reduced inflammatory markers and improved symptoms in rheumatoid arthritis and exercise-induced muscle damage, though studies are small (n=12-50) and results lack independent replication across research groups.

Resveratrol shows probable efficacy for joint health, particularly in knee osteoarthritis pain reduction and functional improvement. Evidence comes from multiple human RCTs with consistent positive results, but sample sizes are modest (n=57-137) and most studies are relatively short-term (12 weeks to 6 months).

CoQ10 shows probable efficacy for joint health in humans, particularly for osteoarthritis and rheumatoid arthritis, with consistent positive results across multiple human studies demonstrating reduced inflammation, improved tissue healing, and inhibition of cartilage-degrading pathways. However, evidence is limited to small-to-moderate RCTs and observational studies without large-scale replication.

Probiotics show probable efficacy for joint health, particularly in osteoarthritis and rheumatoid arthritis, with consistent benefits in pain reduction and inflammatory markers across multiple human trials. However, evidence is limited by small sample sizes, heterogeneous interventions, and lack of independent replication across diverse populations.

Vitamin K2 (menaquinone-7) shows probable benefits for bone health and may reduce joint inflammation markers in rheumatoid arthritis, supported by 3 human RCTs and mechanistic evidence. However, efficacy for general joint health remains incompletely proven due to limited sample sizes and lack of independent replication.

Boron shows probable efficacy for joint health based on one small human RCT demonstrating 50% improvement in osteoarthritis symptoms, supported by epidemiologic patterns and mechanistic evidence, but efficacy remains unproven due to limited human trial data and lack of independent replication.

Maca root shows probable efficacy for joint health based on one human RCT demonstrating comparable symptom relief to glucosamine sulfate, supported by mechanistic studies suggesting chondroprotective effects. However, evidence remains limited to a single human trial and lacks independent replication.

Black seed oil (Nigella sativa) shows probable efficacy for reducing osteoarthritis pain and improving quality of life in humans, supported by multiple small-to-moderate RCTs with consistent positive results. However, effect sizes vary and study quality is modest, preventing a higher tier classification.

Glucosamine + chondroitin demonstrates probable efficacy for knee osteoarthritis pain relief, with multiple human RCTs showing modest but statistically significant improvements. However, evidence for structural joint protection and functional improvement remains inconsistent and modest.

B vitamin complex shows probable benefit for joint health, particularly for osteoarthritis pain when combined with NSAIDs, supported by multiple human RCTs with modest effect sizes. However, recent observational data suggests potential harm at higher intakes, creating uncertainty about optimal dosing and long-term safety.

Selenium supplementation shows probable efficacy for Kashin-Beck disease (KBD), a selenium-deficiency arthropathy endemic to specific regions, with meta-analyses demonstrating radiologic improvement and prevention of new lesions. However, evidence for selenium's benefit in common joint conditions like rheumatoid arthritis and osteoarthritis remains inconclusive in humans.

Sulforaphane shows probable efficacy for joint health based on one small human proof-of-concept trial and multiple animal studies demonstrating cartilage protection and anti-inflammatory effects. However, clinical efficacy in humans remains unproven—only one RCT exists and it measured bioavailability/protein changes, not clinical outcomes.

Pomegranate extract shows probable efficacy for joint health in rheumatoid arthritis, with consistent benefits demonstrated across multiple human studies. However, evidence remains limited by small sample sizes, short study durations, and modest effect sizes that suggest adjunctive rather than primary therapeutic benefit.

Grape seed extract shows probable efficacy for joint health based on consistent findings across multiple animal models of arthritis and one exploratory human clinical trial, but human evidence remains limited and underpowered. Mechanism involves anti-inflammatory pathways and suppression of bone/cartilage destruction.

Olive leaf extract shows probable efficacy for joint health, particularly knee osteoarthritis, with consistent benefits demonstrated across multiple human RCTs and animal studies. However, effects are modest, sample sizes are small-to-moderate, and results are not uniformly strong across all populations tested.

MSM shows modest benefits for knee osteoarthritis pain and function in some human RCTs, but effects are inconsistent across studies and often not clinically meaningful. Evidence quality is mixed with several negative or null trials.

Bromelain, typically combined with trypsin and rutoside, shows probable efficacy for osteoarthritis pain and function in humans, demonstrated across multiple RCTs with improvements comparable to NSAIDs. However, evidence is limited by small sample sizes, inconsistent results in some trials, and lack of independent replication across research groups.

Stinging nettle shows probable efficacy for joint health based on 4 human RCTs demonstrating significant reductions in osteoarthritis pain and functional disability, though sample sizes are small (n=27-92) and most studies involve multi-ingredient formulations, limiting attribution to nettle alone.

Schisandra chinensis shows probable efficacy for joint health, particularly osteoarthritis, with consistent anti-inflammatory and chondroprotective effects demonstrated across multiple animal studies and one human RCT. However, evidence remains limited to a single small human trial; large-scale, independent human validation is needed to confirm clinical benefit.

SAMe shows probable efficacy for osteoarthritis pain and functional improvement based on multiple human trials, but evidence is limited by small sample sizes, short durations, and inconsistent methodologies across studies. Results are encouraging but not conclusive.

Astragalus shows probable efficacy for joint health based on one well-designed human RCT and multiple mechanistic animal/in-vitro studies. A 28-day RCT demonstrated significant knee pain reduction (30% improvement), but the evidence base remains limited to a single human trial with modest sample size.

Hyaluronic acid shows probable efficacy for joint health in humans, with multiple RCTs demonstrating improvements in pain, function, and mobility measures. However, effect sizes are modest, sample sizes remain small to moderate, and results have not been independently replicated across diverse populations with consistent magnitude.

Butyrate shows probable efficacy for joint health, primarily through improving intestinal barrier function and reducing systemic inflammation in osteoarthritis patients. However, evidence is limited to one human RCT with modest sample size and multiple mechanistic studies in animal models or observational designs.

Ginkgo biloba extract (particularly EGb 761 and its bioactive compounds like ginkgetin and isoginkgetin) shows probable efficacy for osteoarthritis through anti-inflammatory and chondroprotective mechanisms in multiple human and animal studies, but evidence is limited by small sample sizes, short durations, and lack of large-scale RCTs.

Panax ginseng and its ginsenosides show probable efficacy for joint health based on one double-blind RCT in humans and multiple mechanistic studies in cell models and animals. The human evidence is limited to a single small trial (n=52) showing pain and disability improvements, while most supporting data comes from in-vitro and animal studies demonstrating anti-inflammatory and chondroprotective mechanisms.

GABA derivatives (primarily pregabalin and gabapentin) show probable efficacy for joint pain, particularly in osteoarthritis, based on limited human RCT evidence. However, the total body of evidence remains small with only 3 eligible RCTs identified in a systematic review, and results are not yet independently replicated across multiple research groups.

Very limited evidence exists for BPC-157 in joint health, consisting of one small retrospective case series (n=17) and one review article. No controlled trials have been conducted to prove efficacy.

TB-500 shows elevated levels in joint diseases and demonstrates anti-apoptotic effects in disc cells, but evidence for therapeutic efficacy in joint health comes only from animal and in-vitro studies plus limited observational data in humans.

MOTS-c shows promise for joint health through animal studies demonstrating reduced cartilage degradation and improved mitochondrial function in osteoarthritis models, but no human trials have been conducted to prove efficacy in patients.

SS-31 shows plausible efficacy for joint health through mitochondrial protection in preclinical models, but human evidence is absent. One human observational study found mitochondrial dysfunction in tendinopathy, and one RCT (MMPOWER-3) evaluated SS-31 in mitochondrial myopathy but did not assess joint-specific outcomes.

AOD-9604 shows promise for joint health in an animal model of osteoarthritis, with enhanced cartilage regeneration and reduced lameness when combined with hyaluronic acid. However, efficacy in humans remains unproven—this is the only available study and it was conducted exclusively in rabbits.

LL-37 is elevated in joint tissues and synovial fluid of patients with joint infections and inflammatory arthritis, suggesting a role in joint pathology, but no human studies demonstrate that LL-37 supplementation improves joint health or reduces joint symptoms.

Kisspeptin shows promise for joint health through in-vitro and animal studies demonstrating anti-inflammatory and anti-senescence effects in chondrocytes, but no human clinical trials have been conducted to prove efficacy in osteoarthritis or joint disease.

GHRP-6 (a ghrelin receptor antagonist) shows mechanistic promise in joint-related conditions based on limited animal and observational data, but efficacy in humans has not been demonstrated. Evidence is primarily indirect—studying ghrelin's effects on cartilage and synovial cells rather than GHRP-6's direct therapeutic use.

Humanin shows promise for joint health through anti-apoptotic and anti-inflammatory mechanisms in animal models, but no human clinical trials have been conducted. All evidence comes from animal studies and one human observational study describing expression patterns rather than therapeutic efficacy.

GDF-11 shows consistent protective effects against osteoarthritis in multiple animal models, with evidence of anti-inflammatory and cartilage-preserving mechanisms. However, no human clinical trials exist to confirm efficacy in patients with joint disease.

Thymalin shows plausible immunomodulatory effects relevant to joint disease in one human observational study and stimulates cell regeneration in aged rat tissue cultures, but efficacy for joint health is not proven in humans and lacks rigorous clinical trial data.

IGF-1 LR3 shows promise for nerve regeneration in a single rat model, demonstrating comparable performance to autologous grafts. However, no human studies exist, and joint health efficacy remains unproven.

MGF shows consistent promise in animal and in-vitro models for joint health and cartilage protection, with plausible mechanisms involving anti-inflammatory pathways and chondrocyte support. However, no human RCTs exist, and the three human observational studies are small and lack proper controls, leaving efficacy in humans unproven.

Omega-3 supplementation shows mixed and largely inconclusive evidence for joint health. While some human RCTs report modest benefits for osteoarthritis pain and rheumatoid arthritis markers, recent large observational studies and Mendelian randomization analyses suggest no causal benefit or even potential harm, and meta-analyses indicate very low certainty of evidence.

Magnesium shows plausible mechanisms for joint health and reduces markers of joint disease in animal models and limited human observational studies, but efficacy in humans remains unproven with only one small RCT and no large, well-designed human trials demonstrating clinical benefit.

Zinc shows mechanistic promise for joint health through antioxidant and anti-inflammatory pathways in cell and animal models, but human efficacy for osteoarthritis remains unproven with no RCTs directly testing zinc supplementation for joint disease in humans.

Berberine shows promising anti-inflammatory and cartilage-protective effects in animal models of osteoarthritis and arthritis, with plausible mechanisms identified. However, no human clinical trials demonstrate efficacy for joint health, making this emerging evidence at best.

NMN shows promise for joint health through animal studies and mechanistic research, but human efficacy for joint conditions remains unproven. Only one animal study directly tested NMN in an osteoarthritis model with positive results.

Alpha lipoic acid shows promising anti-inflammatory and joint-protective effects in a rodent arthritis model, but all evidence is from animal studies with no human trials. Efficacy in humans remains unproven.

Melatonin shows promise for joint health in animal models and one meta-analysis, with positive effects reported in fibromyalgia, osteoarthritis, and intervertebral disc degeneration. However, no rigorous human RCTs exist, and efficacy in humans remains unproven.

Rhodiola rosea (primarily its salidroside component) shows promising effects on joint health markers in animal and in-vitro models, but direct evidence of efficacy for joint health in humans is absent. The two human RCTs identified studied exercise performance and punch power, not joint health outcomes.

Green tea extract (EGCG) shows promise for joint health in animal and in-vitro studies through anti-inflammatory and chondroprotective mechanisms, but evidence from human clinical trials is minimal. Only 1 human RCT exists in this sample, making human efficacy unproven despite consistent mechanistic findings across preclinical models.

Spirulina shows plausible mechanisms for joint health support in animal models and cell culture, with evidence of anti-inflammatory and antioxidant effects. However, no human clinical trials exist, and efficacy in humans remains unproven.

Fenugreek shows consistent anti-arthritic effects in rodent models of rheumatoid arthritis, reducing inflammation markers and edema more effectively than indomethacin in some measures. However, no human clinical trials exist, so efficacy in humans remains unproven.

Vitamin C shows mechanistic promise for joint health through collagen synthesis and antioxidant effects, but human evidence for osteoarthritis prevention or treatment is inconsistent and largely negative. Most positive findings come from deficiency reversal (scurvy) or animal/cell culture studies.

Vitamin B12 (methylcobalamin) shows plausible promise for joint health when combined with other compounds in small human studies, but efficacy is not proven and most evidence comes from non-joint-specific outcomes or combination formulas rather than B12 alone.

Vitamin E shows plausible anti-inflammatory and antioxidant effects in joint tissue, but human RCT evidence for symptomatic joint health improvement is weak and inconsistent. Most positive findings come from biomarker studies or observational data; clinical efficacy for osteoarthritis pain and function remains unproven.

Copper supplementation shows promise for reducing cartilage and bone lesions in developing foals, with consistent effects across multiple animal studies. However, all evidence is from equine models; no human trials exist to demonstrate efficacy for joint health in humans.

Fisetin shows consistent promise for joint health in animal models and cellular studies through senolytic and anti-inflammatory mechanisms, but human efficacy remains unproven—only observational studies exist with no randomized controlled trials demonstrating clinical benefit.

Spermidine shows consistent mechanistic benefits for joint and disc health in animal and cell culture studies through autophagy activation, but no human clinical trials exist to prove efficacy in patients with joint disease.

Urolithin A shows consistent protective effects against osteoarthritis and joint degradation in animal models and cell cultures through mitophagy and anti-inflammatory mechanisms, but human evidence is limited to a single observational study without control group or placebo comparison.

TUDCA shows promise for joint health through multiple mechanistic pathways in cell and animal models, but evidence is limited to in-vitro studies, one small human observational study, and one animal study. Efficacy in humans is not yet proven.

Beta-glucans show immunomodulatory potential in animal models of arthritis and spondyloarthritis, but human efficacy for joint health remains unproven. Only one human RCT exists (in rats, not humans), and most evidence comes from mechanistic studies in animal disease models rather than direct efficacy trials.

Cordyceps compounds show anti-inflammatory and anti-catabolic effects on joint cells and tissues in laboratory and animal models, with plausible mechanisms for osteoarthritis management. However, no human randomized controlled trials exist; evidence is limited to cell culture studies, one small human observational study, and one animal model.

Reishi shows plausible anti-inflammatory and immunomodulatory effects on joint health in multiple animal models of rheumatoid arthritis and osteoarthritis, but efficacy is not yet proven in humans. Only 2 human observational studies exist with limited detail on actual clinical outcomes.

Chaga (Inonotus obliquus) shows plausible anti-inflammatory effects on joint health in animal models, but no human trials have been conducted. Efficacy is suggested but not proven in humans.

Epicatechin shows plausible mechanisms for joint health through anti-inflammatory and senotherapeutic pathways in preclinical models, but no direct human evidence of efficacy for joint or osteoarthritis outcomes exists in the provided abstracts.

Pterostilbene shows consistent anti-inflammatory and antioxidant effects in animal models of osteoarthritis, with multiple studies demonstrating cartilage protection and reduced joint degradation. However, no human clinical trials exist, limiting evidence to animal studies and in vitro work.

Ecdysterone shows consistent anti-inflammatory and chondroprotective effects in multiple animal models of joint disease, with mechanisms involving autophagy activation and NF-κB pathway inhibition. However, no human clinical trials exist to prove efficacy in humans, limiting conclusions to preclinical plausibility.

Cistanche has not been studied for joint health in humans. One human RCT shows benefits for muscle strength in untrained individuals, but this does not address joint health specifically. No human evidence directly supports efficacy for joint health goals.

Tribulus terrestris shows promise for joint health through anti-inflammatory and antioxidant mechanisms demonstrated in multiple animal models and one human exercise study, but lacks direct clinical evidence of efficacy for established joint conditions like osteoarthritis or rheumatoid arthritis in humans.

Methylene blue shows promise for joint health in one human RCT (diskogenic low back pain with intradiskal injection), but evidence is limited to a single small trial with mixed results in animal and in-vitro studies that show concerning dose-dependent toxicity to cartilage and nucleus pulposus cells.

Pregnenolone shows mechanistic promise for joint health through TRPM3 channel modulation in rheumatoid arthritis cells, but evidence is limited to observational studies and in-vitro findings with no human RCTs demonstrating clinical efficacy.

Rapamycin shows mechanistic promise for joint health through mTOR inhibition in animal models and cell studies, but human evidence is limited to observational studies with mixed results—some showing benefit in rheumatoid arthritis while others report worsened osteoarthritis with hyperglycemia.

Lion's Mane (Hericium erinaceus) shows promise for joint health based on multiple animal studies demonstrating reduced cartilage degradation and pain in osteoarthritis models, but no human clinical trials exist to prove efficacy in humans.

Bacopaside I, a component of Bacopa monnieri, shows consistent anti-arthritic effects in rat models of rheumatoid arthritis through multiple mechanisms, but no human efficacy data exists. While animal evidence is mechanistically sound and replicated across two independent studies, efficacy in humans remains unproven.

PQQ shows consistent protective effects against osteoarthritis and joint degeneration in multiple animal models through antioxidant and anti-inflammatory mechanisms, but no human clinical trials exist to demonstrate efficacy in humans.

L-theanine shows promise for joint health based on one animal study demonstrating reduced osteoarthritis progression in rats, but no human trials exist to confirm efficacy. Most evidence is mechanistic or focused on unrelated health outcomes.

Acetyl-L-carnitine shows promise for joint health in animal models of osteoarthritis and one small human observational study for carpal tunnel syndrome, but efficacy in humans is not yet proven. No rigorous RCTs exist for joint health outcomes.

L-Citrulline shows mechanistic promise for joint health through nitric oxide pathways, but evidence is limited to animal models and mechanistic studies in humans with arthritis. No human RCTs have directly tested L-Citrulline supplementation for joint health outcomes.

HMB shows plausible benefits for joint health and musculoskeletal function based on animal studies and limited human data, but efficacy in humans remains largely unproven. Most evidence comes from animal models examining cartilage composition and bone properties rather than direct joint health outcomes.

BCAAs show promise for reducing exercise-induced muscle soreness and supporting muscle strength in joint-related contexts, but evidence is limited to small human studies and animal models with no large-scale RCTs demonstrating clinically meaningful joint health benefits.

L-arginine shows plausible mechanisms for joint health through nitric oxide pathway modulation and anti-inflammatory effects, but evidence is limited to mechanistic studies in animals and observational data in humans with rheumatoid arthritis. No human RCTs directly demonstrate efficacy for joint health outcomes.

GHK-Cu has been studied for joint health primarily through in-vitro and review-level evidence. No human clinical trials demonstrate efficacy for joint health, and the available data is limited to mechanistic studies on osteoblasts and one tissue regeneration review mentioning the compound among many emerging platforms.

KPV has been studied only in laboratory cell culture models for joint health, with no human trials or animal efficacy studies demonstrating clinical benefit. Evidence is purely preliminary and mechanistic.

FOXO4-DRI is a senolytic peptide studied only in vitro for removing senescent cells from expanded chondrocytes used in cartilage repair. No human or animal efficacy data exists for joint health outcomes.

Cardiogen is not studied as a treatment for joint health. The single abstract discusses transthyretin amyloidosis presenting with musculoskeletal symptoms and does not evaluate Cardiogen's efficacy for any joint condition.

Only one animal cell culture study exists for Prostatilen and joint health, showing stimulation of cartilage cell growth in vitro at specific concentrations. No human evidence, clinical trials, or direct joint health outcomes have been demonstrated.

Cortexin's effect on joint health is not established. The single available study tested polypeptide effects on tissue cell cultures in rats, with no direct assessment of joint function or cartilage regeneration outcomes relevant to joint health.

Milk thistle (silibinin) has not been proven effective for joint health in humans. The only direct evidence comes from a single 2024 in-vitro study showing silibinin alters chondrocyte cell behavior, but this does not demonstrate clinical efficacy for joint health in living organisms.

Aged garlic extract has been studied for potential anti-inflammatory and antinociceptive effects relevant to joint health, but all available evidence consists of reviews discussing mechanistic pathways and animal studies in dogs. No human clinical trials for joint health efficacy exist in this dataset.

No credible evidence supports saw palmetto for joint health. The two PubMed abstracts retrieved are entirely irrelevant to this health goal—one describes fungal taxonomy and the other reviews misinformation in alopecia literature, merely listing saw palmetto as an unproven 'natural cure' without any joint health data.

Iron supplementation has not been studied for joint health specifically in any of the 34 retrieved abstracts. All studies examine iron for anemia, blood transfusion prevention, cognitive development, or general nutritional status—not joint-related outcomes.

Iodine has no demonstrated efficacy for joint health. The only human RCT studying iodine supplementation in an osteoarthritic condition (Kashin-Beck disease) found no significant difference in joint pain, mobility, or radiologic abnormalities between supplementation and control groups.

No evidence supports chromium supplementation for joint health. The 5 available studies focus exclusively on metabolic outcomes (diabetes, glucose control, lipid metabolism) in non-joint tissues; none assessed joint-specific outcomes, joint pain, mobility, or cartilage health.

No rigorous human evidence supports biotin for joint health. The three available abstracts are reviews that mention biotin only tangentially—one explicitly identifies it as an 'unfounded' alopecia therapy, another discusses its role in skin/hair (not joints), and the third is unrelated to biotin entirely.

Astaxanthin has only been studied in vitro for joint health, with no human trials or animal model evidence supporting efficacy for actual joint health outcomes. In-vitro data shows astaxanthin reduces oxidative stress markers in immobilized muscle cells, but this does not constitute proof of clinical benefit for joint health.

DIM is mentioned as a 'promising supplement' for breast cancer patients in a single narrative review, but there is no rigorous evidence demonstrating efficacy for joint health specifically. The abstract provides no data on joint-related outcomes.

Nattokinase has not been studied for joint health in humans. The only available evidence consists of one human RCT focused on myocardial infarction (not joint-related) and one animal study examining diabetic retinopathy—neither addresses joint health efficacy.

Colostrum has not been demonstrated to provide efficacy for joint health in humans. The abstracts provide no direct evidence that colostrum supplementation improves joint health outcomes.

Apigenin has not been studied for joint health in humans or animals. The single available study examined ulcerative colitis (gut inflammation), which is mechanistically distinct from joint health.

Kava-241 reduced joint inflammation in a single murine arthritis model, but no human efficacy data exists for joint health. Current evidence is limited to animal studies and cannot establish proven efficacy in humans.

Passionflower has not been studied in any published human trials or animal studies specifically for joint health. The only available abstract is a review article that mentions medicinal plants generally used for chronic pain in pets but provides no specific data on passionflower's efficacy.

Lemon balm (Melissa officinalis) has not been studied for joint health in humans. The two available abstracts address cognitive effects in Alzheimer's disease and intestinal motility in sheep—neither relevant to joint health.

CLA has not been proven effective for joint health in humans. The only human RCT available tested CLA in horses (not humans), and mechanistic reviews suggest plausibility, but no human clinical trials demonstrate efficacy for joint health outcomes.

No evidence supports lithium orotate for joint health. The single available study examined lithium's effects on cognitive and psychiatric symptoms in a schizophrenia model, not joint health outcomes.

Whey protein was studied alongside resistance training for muscle growth, but the single human observational study does not demonstrate efficacy for joint health specifically. No evidence directly supports whey protein for joint health outcomes.

D-Ribose has no demonstrated efficacy for joint health. The single available abstract discusses HNE-induced chondrocyte apoptosis and glutathione-S-transferase protection—a mechanistic review that does not study D-Ribose at all.

Forskolin's effects on joint health are supported only by in-vitro mechanistic studies showing it can modulate chondrocyte responses through cAMP signaling. No human efficacy data exists for joint health outcomes.

Alpha-GPC has not been studied for joint health. The single available study examined DHA repletion in tissue using alpha-GPC as a delivery vehicle for omega-3 fatty acids in developing mice, with no assessment of joint outcomes.

Phosphatidylserine has not been demonstrated to have efficacy for joint health in any human clinical trials. The evidence consists entirely of mechanistic studies, observational biomarker research, and animal/in-vitro work showing phosphatidylserine as a component of joint-related processes, not as a therapeutic intervention.

CDP-Choline has not been studied for joint health in any of the available literature. The four identified abstracts discuss CDP-Choline (citicoline) only in the context of neurological conditions (cognitive impairment, head trauma recovery, epidural fibrosis prevention) and COVID-19 antiviral activity—none address joint health, osteoarthritis, cartilage, or musculoskeletal outcomes.

No human or animal studies directly assess Huperzine A for joint health. Available abstracts only mention Huperzine A in the context of Alzheimer's disease research as an acetylcholinesterase inhibitor, with no relevance to joint health outcomes.

No human evidence exists for piracetam and joint health. The two available studies examine levetiracetam (a different compound in the same drug class), not piracetam, with mixed results in rat models only—one showing anti-inflammatory benefits and one showing potential weakening of bone strength at low doses.

No direct evidence that uridine supplementation improves joint health in humans. The identified studies examine uridine's biochemical role in cartilage and tendon metabolism, but none demonstrate efficacy of uridine as a therapeutic intervention for joint conditions.

Vinpocetine shows promise for osteoarthritis protection in a single animal study, but efficacy is not proven in humans. Only one animal model study exists with no human clinical trials to support therapeutic use.

Beta-alanine has not been studied specifically for joint health in humans. Available evidence consists of mechanistic reviews and one observational study on air pollutant exposure, neither of which directly assess beta-alanine's efficacy for joint health outcomes.

Taurine has not been demonstrated to work for joint health in humans. The 23 articles retrieved are largely irrelevant to joint health—most address cardiovascular, muscle, neurological, or gastrointestinal outcomes in animal and cell models, with no human joint health studies present.

D-Aspartic acid (D-Asp) has not been demonstrated to improve joint health in any human studies. The research consists entirely of mechanistic and genetic association studies with no clinical efficacy data.

No human evidence exists for leucine supplementation and joint health. Available studies focus on muscle protein synthesis and cardiac function through mTOR signaling, with no direct assessment of joint health outcomes.

Tryptophan supplementation activates intestinal aryl hydrocarbon receptor signaling in healthy subjects, but there is no evidence it improves joint health outcomes. The single human RCT available does not measure or report any joint-related endpoints.